GLP-1 Market
LLY $1409.38 ▼ -0.1% NVO $40.19 ▼ -0.6% PFE $30.00 ▼ -2.2% VKTX $26.09 ▼ -2.8% KLRA $12.58 ▲ +3.5% GPCR $20.35 ▼ -0.6% RHHBY $59.18 ▼ -2.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pemafibrate

Company
Tokyo Women's Medical University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 4, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pemafibrate and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07562178

    Pemafibrate for Symptomatic ICAS RCT

    Not yet reported Tokyo Women's Medical University 270 participants Est. completion 2028-12-31 42 sites Stand-alone
    Cardiovascular disease Other conditions: Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia
    View official trial listing →
  • Recruiting NCT NCT07634484

    A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins

    Not yet reported Kowa Company, Ltd. 120 participants Est. completion 2027-07-31 10 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Terminated NCT NCT03071692

    Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

    Not yet reported Kowa Research Institute, Inc. 10544 participants Est. completion 2022-07-27 888 sites Stand-alone
    Type 2 diabetes Other conditions: Dyslipidemia
    View official trial listing →
  • Terminated NCT NCT03345901

    PROMINENT-Eye Ancillary Study (Protocol AD)

    Not yet reported Jaeb Center for Health Research 18 participants Est. completion 2019-04-03 71 sites Stand-alone
    Other conditions: Diabetic Retinopathy, Diabetic Macular Edema
    View official trial listing →
  • Completed NCT NCT03350165

    A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

    Not yet reported Kowa Company, Ltd. 118 participants Est. completion 2020-06-30 16 sites Stand-alone
    Other conditions: Non-Alcoholic Fatty Liver Disease
    View official trial listing →
  • Completed NCT NCT04079530

    A Clinical Pharmacology Study of K-877 Controlled Release Tablet

    Not yet reported Kowa Company, Ltd. 60 participants Est. completion 2019-12-24 1 site
    Other conditions: Dyslipidemias
    View official trial listing →
  • Completed NCT NCT04714151

    A Phase III Confirmatory Study of K-877 Extended Release Tablet

    Not yet reported Kowa Company, Ltd. 356 participants Est. completion 2021-09-25 11 sites
    Other conditions: Dyslipidemias
    View official trial listing →
  • Completed NCT NCT04716595

    A Phase III Long Term Study of K-877 Extended Release Tablet

    Not yet reported Kowa Company, Ltd. 121 participants Est. completion 2022-06-13 14 sites
    Other conditions: Dyslipidemias
    View official trial listing →
  • Completed NCT NCT04998981

    A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

    Not yet reported Kowa Company, Ltd. 353 participants Est. completion 2023-02-02 33 sites
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT05923281

    A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

    Not yet reported Kowa Company, Ltd. 71 participants Est. completion 2024-08-07 22 sites
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT06247735

    Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

    Not yet reported Kowa Research Institute, Inc. 46 participants Est. completion 2026-07-23 38 sites
    Other conditions: Primary Biliary Cholangitis
    View official trial listing →
  • Completed NCT NCT06525311

    A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

    Not yet reported Kowa Research Institute, Inc. 17 participants Est. completion 2025-04-09 10 sites
    Other conditions: Primary Biliary Cholangitis, Compensated Cirrhosis
    View official trial listing →
  • Status unknown NCT NCT06623539

    Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

    Not yet reported Yokohama City University 360 participants Est. completion 2026-03 1 site Stand-alone
    Other conditions: Non Alcoholic Fatty Liver Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.